Abstract library

1401 results for "pituitary tumors".
#157 Multiple Endocrine Neoplasia Type 1 (MEN-1), Hadassah-Hebrew University Medical Center experience
Introduction: MEN 1 is an autosomal dominant genetic disorder with a prevalence of 2-4 per 100,000. The main manifestations are parathyroid (PT), gastroenteropancreatic (GEP) and pituitary tumors, but may affect other organ systems as well. MEN 1 is associated with significant morbidity and mortality, with up to 50% dying before the age of 50. Treating MEN 1 patients presents a unique diagnostic and therapeutic challenge.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Sameer Kassem
Authors: Kassem S, Glaser B, Barak D, Fraenkel M, ...
#930 Distinct Expression of Splicing Variants of the Human MEN1 (Multiple Endocrine Neoplasia Type 1) Gene in Various Pituitary Adenomas
Introduction: MEN1 is an autosomal-dominant tumor syndrome characterized by the occurrence of tumors in multiple endocrine tissues, including parathyroid, enteropancreatic neuroendocrine and anterior pituitary. The MEN1 gene consists of 10 exons transcribed into a 610 a.a. protein. It was reported that heterogeneity of human MEN1 gene transcripts related to variation in their 5’ UTR. Six distinct exsons1 (e1A-e1F) were isolated using RNA from thymus, pancreas and kidney.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Atsushi Ozawa
Keywords: MEN1, pituitary
#2006 The Frequency of Patients with Giant Pituitary Tumors from Retrospective Data
Introduction: In this scientific article an author discusses the results of researches 121 patients with different by volume formations of sellar area, from them - men - 59 (48,9%), women - 62 (51,1%).
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Professor Yulduz Urmanova
#80 Metastatic growth hormone secreting pituitary carcinoma treated with peptide receptor radionuclide therapy
Introduction: Pituitary carcinoma (PC) is an extremely rare condition defined by the presence of adenohypophyseal neoplastic tissue outside the pituitary. Clinical experience regarding diagnosis, management and prognosis of PC is very limited. Growth hormone (GH) secreting PC is even rarer and represents a particular challenge to clinical practice. Therapeutic modalities utilized to treat PC include surgery, radiation, hormonal therapy, and cytotoxic drugs. Peptide Receptor Radionuclide Therapy (PRRT) is an emerging therapeutic modality that involves the targeted delivery of an ablative dose of radiolabelled somatostatin analog. PRRT has been applied to various neuroendocrine tumors and results in prolonged survival and enhanced quality of life. As yet, this therapy has not been applied to malignant pituitary tumors.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Sameer Kassem
#141 Incidence of second primary tumors in patients with neuroendocrine tumors
Introduction: Based on epidemiological data from SEER 1950-1999, 22.4% cases of non-carcinoid second primary tumors have been described in patients diagnosed with neuroendocrine tumors. The incidence of this type of tumors varies, depending on the series assessed.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Juan Manuel OConnor
Authors: Pesce V, OConnor J, Mendez G, Bestani C, ...
#2227 Screening Benefits in MEN1-Associated Pituitary Adenomas
Introduction: MEN1 is an autosomal-dominant syndrome characterized by tumors of the parathyroid glands (95%), endocrine pancreatic-gastroenteric tract (40%), and pituitary gland (30%).
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: md Sabrina Chiloiro
#19 Antitumor activity of Pasireotide (SOM230) alone and in combination with Everolimus (RAD001) in DU-145 human prostate cancer model
Introduction: Pasireotide (SOM230) is a novel multi-receptor ligand somatostatin analogue with high affinity for somatostatin receptor subtypes sst1,2,3 and sst5. Like octreotide, which binds primarily to sst2, it inhibits hypersecretion of hormones from patients with functional pituitary tumors and gastroenteropancreatic neuroendocrine (GEP/NET) tumors. In addition, tumor shrinkage has been observed with both compounds in patients with acromegaly, Cushing’s disease and GEP/NETs, but its tumor-reducing mechanism of action has so far not been revealed. In patients with breast and liver cancer, octreotide had little or no antitumor activity.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr. Herbert A. Schmid
Authors: Schmid H A, Chiara L, Nuciforo P, ...
#61 Multiple tumors in patients with pancreatic neuroendocrine tumours: morphological and immunohistochemical characteristics
Introduction: Pancreatic islet cell tumors occur in 80% of patients with MEN 1. Tumors are often multicentric. They often produce multiple peptides and biogenic amines.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Prof Larisa Gurevich
#111 Atypical lung carcinoid tumor metastatic to endocrine glands and bone marrow
Introduction: Bronchopulmonary neuroendocrine tumors (BP-NETs) comprise 20% of all lung cancers. Typical low grade carcinoid tumors (TC) represent the majority of BP-carcinoids. Intermediate grade atypical carcinoid tumors (AC) are less often encountered but more aggressive. Although metastatic dissemination to mediastinal lymph nodes, liver, skeleton and central nervous system (CNS) is common, involvement of the endocrine glands has rarely been reported.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Vasiliki Daraki
#1093 38 Years of Experience in a Single Centre on Neuroendocrine Pancreatico-Duodenal Tumors in Multiple Endocrine Neoplasia Type 1 Syndrome
Introduction: Multiple Endocrine Neoplasia type 1 (MEN1) syndrome has an autosomal dominant transmission. Combination of tumors: parathyroid, pituitary and pancreatico-duodenal (PD) NETs. PD NETs in MEN1 syndrome show propensity for malignant degeneration.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Doctor Valbona Lico